

A---B designates an optional double bond,

R₁ is (a) -R'N(R")₂ wherein R' is C₁-C₅ straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR"" or -OC(O)R"" moiety wherein R"" is hydrogen or C₁-C₅ straight or branched chain alkyl, (b) -Q wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) -R'X wherein R' is C₁-C₅ straight or branched chain alkyl and X is halogen, (d) -R'C(O)N(R")₂ wherein R' is a direct bond or C₁-C₅ straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR"" or -OC(O)R"" moiety wherein R"" is hydrogen or C₁-C₅ straight or branched chain alkyl, (e) -R'C(O)OR" wherein R' is a direct bond or C₁-C₅ straight or branched chain alkyl and R" is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR"" or -OC(O)R"" moiety wherein R"" is hydrogen or C₁-C₅ straight or branched chain alkyl, (f) -R' wherein R' is C₁-C₅ straight or branched chain alkyl, or (g) -R'OR"" wherein R' is C₁-C₅ straight or branched chain alkyl and R"" is hydrogen or C₁-C₅ alkyl;

G is hydrogen, halogen, or -OR₂ wherein R₂ is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR"", -OC(O)R"", C(O)OR"", or -C(O)R" moiety wherein R"" is hydrogen or C₁-C₅ straight or branched chain alkyl; and

R₃ is (a) C₁-C₁₂ straight or branched chain alkyl, (b) -OR""", in which R"" is a straight chain or branched C₂-C₉ alkyl which may be substituted at the terminal carbon atom by a phenyl group, or (c) -(CH₂)_n OR"" wherein n is an integer of 1 to 7 and R"" is hydrogen or C₁-C₅ alkyl.

REMARKS

Claim 17 has been amended and claims 9-16 have been canceled herein. Claims 1-8 and 17 appear in this application for the Examiner's review and consideration. No new matter has been added. A marked up copy of the claim amendments appears in Appendix A, while a listing of all current claims appears in Appendix B.

In response to the Examiner's restriction requirement, Applicants specifically elect Group I, claims 1-8 and 17, drawn to compounds and compositions.

No fee is believed to be due for this submission. Should any fees be due, however, please charge such fees to Winston & Strawn Deposit Account No. 501-814.